6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

Robert C Bransfield, MD, continues to share how vector-borne infections may trigger psychiatric symptoms not through direct brain infection, but by disrupting immune signaling and gene expression.

Screening for an immunological biomarker in the nasal passage can effectively rule out a respiratory virus — reducing the need for conventional PCR tests.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuous education opportunity.

A retrospective study finds no significant difference in treatment failure between obese and non-obese patients.

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

Dual ACIP votes endorse RSV antibody protection for infants and expand no-cost access through the Vaccines for Children program.

New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.

The philanthropic organization plans to provide the gift over the next 5 years, and is in contrast with what is happening with US vaccine funding to the organization as well as the country's changing immunization policies.

Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

More than 80% of patients had drug-related problems, highlighting the need for inpatient antiretroviral stewardship.

Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.

New longitudinal study findings suggest booster vaccination may not be necessary despite declining antibody levels.

Application of GBD methods reveals substantial RSV-attributable hospitalizations and informs vaccine and surveillance strategies.

At ASM Microbe 2025, Meghan Starolis, PhD, discusses her presentation on antiviral testing including the advantages and limitations to genotypic and phenotypic testing and looking at how this can affect the immunocompromised population.

Single-dose, nonvaccine antiviral shows significant seasonal prophylactic efficacy and favorable safety profile in over 5000 healthy adults.

American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.

In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government funding and how it may shake up and limit basic science research.

At ASM Microbe 2025, a Puerto Rico study links increased fungal spore concentrations to rises in viral respiratory infections, suggesting potential early warning utility.

FDA and CDC warn consumers as recalled heat-and-eat meals sold at Kroger and Walmart are tied to multiple hospitalizations, one pregnancy loss, and ongoing risks.

At ASM Microbe 2025, a cross-sectional study highlights Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.

At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.

At ASM Microbe 2025, researchers underscored the role of NAAT in outpatient CDI diagnosis and raised concerns over PPI-related risk in older, health care–associated cases.

A study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.